


COVID-19 RESPONSE MECHANISM

ASLM BRIEFING

MAY 2021

THE GLOBAL FUND'S COVID-19 RESPONSE




C19RM supports the following areas:

- COVID-19 Response
- COVID-19 related adaption of programs to fight HIV, tuberculosis & malaria
- Strengthening health and community systems

C19RM 2020 | US\$759 MILLION

C19RM Awards by Priority Area and Type (USD 759 million)



The Global Fund approved a total of US\$759 million for C19RM, as follows:

- **US\$243 million (32%)** for mitigating COVID-19's impact on HIV, TB and malaria programs;
- **US\$442 million (58%)** for reinforcing national COVID-19 responses; and
- **US\$74 million (10%)** for urgent improvements in health and community systems.


The US\$759 million included awards of \$182 million for COVID-19 diagnostics; US\$276 million for Personal Protective Equipment (PPE); and around US\$12 million for Oxygen.

All awards have been consistent with WHO technical guidance and were made based on Country Coordinating Mechanism (CCM)-endorsed requests.

IN 2021 C19RM WILL EXPAND SUPPORT BY 5X OVER 2020

C19RM invested **US\$759 million in 2020** and this support is expected to **expand by close to 5 times in 2021** with additional support from donors.

C19RM 2020 Award, 2021 Base and Above Base Allocation \$million



* Note that all values are in US\$ million. 2020 C19RM Award values exclude \$231 million in grant flexibilities. 2021 C19RM Base and Above Base Allocation are not confirmed awards until full review and approval of funding requests by Global Fund.

C19RM 2021 | OVERVIEW

- Mechanism was successful in 2020 and maintains speed and agility, with **robust end-to-end process** and strengthened and expanded partner and community engagement in 2021.
- The United States government announced **US\$3.5 billion** to the Global Fund's COVID-19 response.
- Germany also announced a contribution of **€140 million**. Other donors may come on board.
- In 2021 C19RM builds on strong guidance from the Board, lessons learned in 2020 and an audit from the Global Fund's independent Office of the Inspector General (OIG) audit.
- From OIG findings:
 - In comparison with seven peer organizations, C19RM was the last mechanism to be announced but one with the highest conversion rates in funding approval.
 - The OIG found a robust, consultative and inclusive process to quickly support countries by timely approving funding requests.
- Extension unanimously approved by the Global Fund Board on **31 March 2021**.

C19RM 2021 | WHAT'S NEW?



C19RM Allocation letters were sent to eligible country and multicountry recipients. The letters include:

1. **C19RM Base Allocation**; and
2. **C19RM Above Base Allocation**: portion of additional funds.



Fast-track Funding Requests should be sent first for time-critical COVID-19 health products.

Full Funding Requests will be submitted through scheduled **submission windows**.



In addition to already existing **CCM** requirements for community **engagement, a new requirement** includes close coordination with **national COVID-19 response** coordinating bodies.

Other updated areas:

- Upfront technical guidance
- Complete application package
- List of eligible interventions
- Strengthened assurance, accountability, M&E
- Enhanced oversight, transparency and reporting

ELIGIBILITY




WHO IS ELIGIBLE?

All current implementing countries, including regional / multicountry recipients, that are receiving funding from the Global Fund.


C19RM APPLICATIONS | DEVELOPMENT OF C19RM FUNDING REQUESTS

Applicants are invited to submit requests to access C19RM Funding through a **C19RM Full Funding Request** and/or a **Fast-track Funding Request**



* And associated costs for their effective deployment

C19RM APPLICATIONS | FAST-TRACK FUNDING REQUEST



Countries are able to access a portion of their C19RM Base Allocation to expedite fulfilment of **urgent procurement requirements**¹, which includes:

PPE

Diagnostics

Therapeutics²
(oxygen and related equipment)

in line with WHO guidance, COVID-19 Strategic Preparedness and Response Plans, and consulted with national COVID-19 response coordinating bodies.




NOTE: Fast-track submissions to start **7 April 2021** with expedited review process.

¹ Applicants should consider including their forecasted needs for these commodities for the **next 6 to 12 months** and start preparing these requests as soon as possible given **procurement and supply chain lead times**. The costs related to the effective deployment of these commodities will also be covered.

² Applicants are encouraged to include oxygen in their future C19RM funding requests to **rapidly scale-up oxygen provision** and treat severe COVID-19

C19RM APPLICATIONS | C19RM FULL FUNDING REQUESTS

- Recognizing that some types of funding requests may take longer to develop, countries will be able to submit their C19RM Full Funding Requests in two parts if needed, as long as their complete submission is received by 30 June 2021.
- Countries are strongly encouraged to submit their C19RM Full Funding Request as soon as possible (by the first submission window date of 14 May 2021) given the urgency needed to respond to the pandemic.
- To access this new financing, the Global Fund requires you to submit an **ambitious and comprehensive funding request**. It should outline prioritized programmatic needs requiring financing using the C19RM Base Allocation amount and beyond the C19RM Base Allocation amount.



All C19RM funding requests must be endorsed by **CCMs**¹.

C19RM 2021 TIMELINES

Submission Window	Date
Fast-Track	As of 7 April 2021
Window 1	14 May 2021
Window 2	31 May 2021
Window 3	15 June 2021
Window 4	30 June 2021




**Deadline to
use funds:**

31 December 2023

- [C19RM Funding Request Tracker](#) published on Global Fund Website.
- This allows the Global Fund and Partners to plan and for Countries to take the time they need to develop more complex Full Funding Requests.
- The Global Fund will evaluate any remaining **unawarded funds** to reassign them to approved and unfunded quality interventions.

OVERVIEW OF C19RM REVIEW PROCESS



KEY


- C19RM FULL FUNDING REQUEST
- FAST-TRACK FUNDING REQUEST

Regular Reporting: Key Data Published on Global Fund Website for Transparency

Partner & Board Engagement: Monthly reviews with Board, GAC/CTAG Partners

TECHNICAL GUIDANCE & PARTNER ENGAGEMENT

- Improved **technical guidance**, application materials and communications.
- **Partners are engaged in-country** during the preparation of funding requests through CCMs.
- **Regional and Global coordination** is continued with partners across a range of forums.



Note: In addition to the CCM endorsement, COVID-19 control and containment interventions need to be endorsed by **COVID-19 response national coordinating bodies**.

TECHNICAL GUIDANCE

Streamlining content and developing strong technical guidance

C19RM Technical Information Note

- Provides applicants with technical guidance on eligible C19RM interventions, based on WHO COVID-19 Response Pillar Framework
- Emphasis on community-led responses

HIV, TB & Malaria Information Note: Mitigation of COVID-19 Effects on HIV, TB & Malaria Services & Programs

- Supports CCMs, national programs for HIV, TB & malaria, & in-country partners with C19RM funding request development

Technical Information Note on Community Systems & Responses: to improve community engagement

- In addition to the interventions covered in the guidance, examples of CRG-related investments during COVID-19

WHO Strategic Preparedness & Response Plan for COVID-19

KEY MESSAGES IN ALLOCATION LETTER

The C19RM Funding Request must:

- Be consistent with applicable **World Health Organization (WHO) guidance**;
- Consider appropriate **community, rights, and gender-related interventions**;
- Align with the **national COVID-19 response** and is **fully endorsed by CCM**;
- Endorsed by the **COVID-19 national response coordinators**;
- Be **evidence-based** and show analysis of program disruptions/adaptations due to COVID-19;
- Identify how C19RM funds **complement domestic and other sources**;
- Explain how the proposed C19RM investments reflect **highest priority interventions**, optimizing for results and Value for Money (efficiency and effectiveness);
- Ensure that C19RM investments lead to **long-term outcomes** and **contribute to future pandemic preparedness and partner engagement**.

SUPPLY OPERATIONS | SCALING ACCESS TO PRODUCTS

- Through C19RM funding the Global Fund will be able to address some of the constraints that countries are facing for **COVID-19 diagnostics, therapeutics** (including O₂) and **infection control**.
- **Fast-track funding request of optimal products**
- **Support materials** including supply availability status, reference prices, lead-times etc. will continue to be posted in the COVID-19 dedicated pages of our website.
- **Product offering on wambo.org** being fully aligned with C19RM eligible interventions for health & "non-health" products (and the HPMT)
- **Engaged with ACT-A** that aims to bring new tools to scale quickly.

The screenshot shows a webpage titled "COVID-19 Health Product Supply". On the left is a navigation menu with items: Overview, Situation Reports & Updates, Response Mechanism, Grant Funding & Flexibilities, Technical Guidance, Health Product Supply (selected), Updates, Diagnostics, Personal Protective Equipment, Treatment and Oxygen Equipment, Procurement Advice, Quality Assurance, Tools Accelerator (ACT-A), and Our Perspective. Below the menu are social sharing icons for Twitter and Facebook, and a print icon. The main content area has a heading "Health Product Supply" and a paragraph: "The COVID-19 pandemic has far-reaching impacts on global health product supply chains. The Global Fund works closely with suppliers, implementers and partners to assess the impact on core health product supplies for Global Fund grants. We provide recommendations for implementers on how to manage this impact and offer channels to ensure the continued flow of quality-assured health products." Below this is a sub-heading "Assessment and recommendations" and a highlighted box containing the text: "As of 22 March 2021, the Global Fund's product and delivery outlook shows the overall impact of COVID-19 on health product supply chains for Global Fund grants remains at **moderate**." Further down, there is another paragraph: "Our health product supply response to the pandemic includes regular category-by-category operational risk assessments, recommendations for implementers and other actions. The resource below details our latest assessment and recommendations." This is followed by a bullet point: "COVID-19 Impact on Health Product Supply: Assessment and Recommendations" with a link "download in English". At the bottom, there is a paragraph: "Health products are a critical component of a country's effective emergency response to COVID-19. Countries can access support to secure products through grant flexibilities and the COVID-19 Response Mechanism. Our documents and pages detail procurement for:" followed by a list of categories: Diagnostics, Personal Protective Equipment, Treatment and Oxygen Equipment, Procurement Advice, and Quality Assurance.

<https://www.theglobalfund.org/en/covid-19/health-product-supply/>

C19RM GUIDELINES | RECOMMENDED PROCUREMENT CHANNELS

Strategic Products

PPM/ wambo.org

or

***Existing UN entity procurement channel where UN entity is PR, provided the PR agrees to provide monthly reporting on visibility from procurement to delivery.**

Mainstream Products

PPM/wambo.org is strongly encouraged

If PRs elect not to use PPM/wambo.org, **can request** to procure through:

***National sourcing channels** provided the PR agrees to provide to GF:

- **procurement performance assurance** (including on quality, speed, volume, price and overall risk); **and**
- **monthly reporting** on visibility from procurement to delivery

***Existing pooled procurement channels** for the grant (GDF, PAHO, UNICEF, UNDP etc.), and GF will work with the PR to obtain:

- **procurement performance assurance** (including on quality, speed, volume, price and overall risk); **and**
- **monthly reporting** on visibility from

Local sourcing advised

National sourcing channels are strongly encouraged



***In all such cases, reporting and other requirements approved by the C19RM Investment Committee will be communicated to the applicant in the C19RM Notification Letter and incorporated into the Grant Agreement.**

https://www.theglobalfund.org/media/10765/covid19_health-product-segmentation_framework_en.pdf

KEY DOCUMENTS | CATEGORY-SPECIFIC GUIDANCE

<https://www.theglobalfund.org/en/covid-19/health-product-supply/>

Overview

Updates & Situation Reports

Response Mechanism ▾

Grant Funding & Flexibilities

Health Product Supply ^

- Diagnostics**
- Personal Protective Equipment
- Treatment and Oxygen Equipment
- Procurement Advice
- Quality Assurance

Health Product Supply

The COVID-19 pandemic has far-reaching impacts on global health product supplies for Global Fund grants. We provide guidance to suppliers, implementers and other stakeholders on how to manage this impact and offer channels for quality-assured health products.

Assessment and recommendations

As of 22 March 2021, the Global Fund's product and delivery impact of COVID-19 on health product supply chains for low- and middle-income countries is **moderate**.

Our health product supply response to the pandemic includes operational risk assessments, recommendations for implementation and procurement advice.

Health Product Segmentation Framework →

Diagnostics

The Global Fund is working closely with key partners, international organizations, governments and technical agencies through a World Health Organization-led consortium to rapidly and equitably support access to COVID-19 health products and diagnostics for low- and middle-income countries. Key resources on procuring and running diagnostics are below.

- [Ordering COVID-19 Diagnostics through the Global Fund: Frequently Asked Questions](#)
download in [English](#) ← **FAQs**
- [PPM Reference Price List for COVID-19 Diagnostics](#)
download in [English](#) ← **Reference prices**
- SARS-CoV-2 Antigen Rapid Diagnostic Test Training Package
download in [English](#) | [Français](#) | [Russian](#)
- List of "optimal" health products, including SARS-CoV-2 diagnostic tests, available through the C19RM Fast-Track
download in [English](#)

Documents related to prior SARS-CoV-2 diagnostic volume allocations are available for download here.

- [Prior SARS-CoV-2 diagnostic volume allocations](#) [2]
- [WHO: Diagnostics Allocations Frequently Asked Questions](#)
- [Diagnostics Consortium Initial Allocation for Cepheid GeneXpert SARS-CoV-2 Tests](#)
download in [English](#)

ELIGIBLE INVESTMENTS

Activities to be funded are aligned with relevant pillars of the WHO COVID-19 Response Pillar Framework:

- **Pillar 1:** Country-level coordination, planning, and monitoring
- **Pillar 2:** Risk communication and community engagement, including infodemic management
- **Pillar 3:** Surveillance, including Epidemiological Investigation and Contact Tracing
- **Pillar 4:** Ports of Entry, International Travel and Transport
- **Pillar 5:** Laboratory and diagnostics
- **Pillar 6:** Infection Prevention and Control, and Protection of the Health Workforce
- **Pillar 7:** Case management, Clinical Operations, and Therapeutics
- **Pillar 8*:** Operational support and logistics
- **Pillar 9:** Maintaining essential health services and systems (Referred to as “Mitigation” in C19RM)
- **Pillar 10:** Vaccination

* For Pillar 8: Operational Support and Logistics and related activities are reflected within other Intervention categories and response Pillars.

PILLAR 5

Laboratory and diagnostics

COVID-19 control and containment:


- Expand and strengthen laboratory and diagnostics capacity.
 - Based on national testing strategies and Lab Packages (Annex 2)
-

Health and Community System Strengthening:

- Specimen transportation networks.
- Quality management systems.
- Lab information systems.
- Equipment management systems.
- Biosafety practices.

C19RM 2021 – Lab Intervention Packages

PACKAGES RESPOND TO THE NEED FOR TAILORED SUPPORT BASED ON COUNTRIES STAGE OF RESPONSE



C19RM 2021 APPLICANT REGISTRATION AND FAST-TRACK


- Out of the total of **129 eligible applicants**, we have received estimated **registration dates for 119** of them (updated as of 12.00, 10 May)
- **43 out of the 119 (or 36%)** that have answered the survey have indicated that, as well as coming for Full Review, they are also planning to come for **Fast-track**.
- **Fast-track applications** already received: The Gambia, India, Philippines, Cambodia, Nepal, Djibouti, Togo, Malawi, Burundi and Tanzania
- Oxygen included in the set of prioritized health products eligible for fast-track.

<https://www.theglobalfund.org/en/covid-19/allocations-and-funding-tracker/>


FAST-TRACK PROJECTED SUBMISSIONS

43 Fast Track Funding Request applications for an estimated total of US\$617m (out of the total of US\$900m reserved for Fast-track)

Projected Fast-track Submissions (#)



Projected Fast-track Submissions (\$)




As of 12.00, Mon 10 May


FULL REVIEW PROJECTED SUBMISSIONS

119 Full Funding Request applications for an estimated total of US\$3.83Bn (including earlier Fast-track amounts)

Projected Full Funding Request submissions (#)



Projected Full Funding Request submissions (\$)



As of 12.00, Mon 10 May



BACK- UP